+ Canine Soft Tissue Sarcomas
Australian company, QBiotics Group Limited, has developed an intratumoural treatment for malignant tumours in dogs. It has been approved for use in MCTs by the APVMA. The active ingredient is tigilanol tiglate (TT) which is a novel small molecule pharmaceutical for use in MCTs, and now it is being trialled on STSs.
A trial of TT for STS in dogs is underway at the Brisbane Veterinary Specialist Centre, home of the Australian Animal Cancer Foundation. The study will provide further efficacy and safety data as well as pave the way for safe and appropriate use of this drug on STS tumours. The study involves up to 10 dogs with the estimated last recruitment in August 2023.
The inclusion criteria are relatively healthy dogs, over one year of age, with a cytological diagnosis of one soft tissue sarcoma tumour without evidence of metastasis.
If you believe you may have a case that meets these criteria, please contact Julia Cathie or Rod Straw at BVSC on 07 3264 9400.